Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing
14 déc. 2023 18h56 HE
|
Eterna Therapeutics
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell...
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors
01 nov. 2023 08h30 HE
|
Eterna Therapeutics
CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell...
Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics
06 sept. 2023 08h00 HE
|
Eterna Therapeutics
mRNA cell engineering strategically targets genes to create novel and potentially superior product profiles for cell transplant therapy applications Novel engineered iPS cell line to be evaluated by...
Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors
05 sept. 2023 08h30 HE
|
Eterna Therapeutics
CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell...
Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing
18 juil. 2023 08h00 HE
|
Eterna Therapeutics
CAMBRIDGE, MASS., July 18, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell...
Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors
11 juil. 2023 08h30 HE
|
Eterna Therapeutics
CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell...
Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel
24 mai 2023 08h30 HE
|
Eterna Therapeutics
CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell...
Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
17 mai 2023 08h30 HE
|
Eterna Therapeutics
Approach is potentially first iPS cell-derived multi-cell-type therapeutic strategy designed to mimic how the human immune system naturally fights disease Presentations to include additional advances...
Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
04 mai 2023 08h30 HE
|
Eterna Therapeutics
Eterna to present data on iPS cell-derived multi-cell-type therapeutic strategy for solid-tumor targeting, nucleic-acid delivery, and targeted gene insertion CAMBRIDGE, Mass., May 04, 2023 (GLOBE...
Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics
02 mai 2023 07h30 HE
|
Eterna Therapeutics
Acquisition includes Exacis’ entire pipeline of engineered cell therapy programs for hematologic and solid tumors CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc....